SALEHI, B.; DEL PRADO, M.; CORTÉS, H.; LEYVA, G.; STOJANOVIC, Z.; DISCO, Y.; KUMAR, J.; DAS, G.; MARTINS, N.; MARTORELL, M.; SHARIFI, M.; CHO, W.; SHARIFI, J.:
Journal of Clinical Medicine 2020, 9(3), 746.
Cardiovascular diseases (CVD) compromises a group of heart and blood vessels disorders with high impact on human health and wellbeing. Curcumin (CUR) have demonstrated beneficial effects on these group of diseases that represent a global burden with a prevalence that continues increasing progressively. Pre- and clinical studies have demonstrated the CUR effects in CVD through its anti-hypercholesterolemic and anti-atherosclerotic effects and its protective properties against cardiac ischemia and reperfusion. However, the CUR therapeutic limitation is its bioavailability. New CUR nanomedicine formulations are developed to solve this problem. The present article aims to discuss different studies and approaches looking into the promising role of nanotechnology-based drug delivery systems to deliver CUR and its derivatives in CVD treatment, with an emphasis on their formulation properties, experimental evidence, bioactivity, as well as challenges and opportunities in developing these systems.